Summary of EGFR mutation status in cell samples of refractory cancer patientsa).

a)EGFR mutation status including wild-type (WT), E746-A750 del (del), L858R and T790M was determined by both IHC and RNA-LNA PCR clamp assays with 11 clinical samples of cancer patients refractory to gefitinib treatment.b)EGFR mutation status determined by IHC analysis is presented by scoring (0, 1+, 2+, 3+) (Figure 8) of immunostaining intensity in cancer cells in primary tumor and disseminated samples of 11 patients (Primary tumor sample/Disseminated and/or metastatic sample). nd, not determined.